From the blog

New study suggests breast cancer drug may shrink mesothelioma tumors

Published: March 27, 2014

After new evidence surfaced suggesting the enzyme aromatase is associated with malignant mesothelioma, Italian scientists began testing breast cancer drug Aromasin (exemestane) on mice and mesothelioma cells.

Designed to inhibit aromatase, Aromasin curbs cell growth in breast cancer patients by helping reduce the amount of estrogen in the body. In the mesothelioma cells and mice, the drug inhibited a glycoprotein necessary for cell migration, thus limiting the tumor growth.

Additionally, when combined with common mesothelioma treatment Alimta, the scientists observed a significant decrease in tumor size. In fact, the Aromasin/Alimta combination showed results even better than the preferred chemotherapy treatment of Alimta and cisplatin.

Because of the overwhelming success of the experiment, the researchers are pushing to begin clinical trials quickly. Because Aromasin is already used to treat breast cancer and is FDA approved, they hope the trials begin soon.

To view the full study, click here.

To view the original release, click here.

Contact Us
Have you received a diagnosis? *